Table 5.
Secondary Endpoint with an Analysis of Covariance Model
| Variable | n | Adjusted Mean (SE) | Adjusted Mean Difference (95% CI) | P value (Between-Group Difference) | |
|---|---|---|---|---|---|
| Teneligliptin Group (n = 8) | Control Group (n = 9) | ||||
| Flow-mediated dilation (%) | 16 | 3.1 (0.6) | 0.4 (0.6) | 2.7 (0.7, 4.7) | 0.013 |
| Baseline diameter (mm) | 16 | −0.6 (0.2) | −0.5 (0.2) | −0.1 (−0.6, 0.4) | 0.57 |
| E/A | 13 | −0.1 (0.1) | −0.2 (0.1) | 0.1 (−0.1, 0.3) | 0.57 |
| E/e’ | 16 | −0.5 (1.7) | −1.2 (1.7) | 0.6 (−4.6, 5.9) | 0.79 |
| Plaque area (mm2) | 6 | −0.3 (0.2) | −0.6 (0.3) | 0.3 (−0.8, 1.4) | 0.44 |
| Fasting plasma glucose (mg/dL) | 15 | −7.7 (11.6) | 24.8 (10.8) | −32.5 (−67.8, 2.8) | 0.07 |
| Hemoglobin A1c (%) | 16 | −0.4 (0.2) | −0.1 (0.2) | −0.3 (−0.9, 0.3) | 0.30 |
| Triglyceride (mg/dL) | 14 | 52.1 (30.8) | −2.9 (26.5) | 55.0 (−36.9, 146.8) | 0.21 |
| LDL-cholesterol (mg/dL) | 16 | −20.7 (5.3) | −9.4 (5.3) | −11.3 (−27.5, 4.9) | 0.15 |
| HDL-cholesterol (mg/dL) | 16 | −1.2 (2.4) | 0.9 (2.4) | −2.1 (−9.5, 5.3) | 0.55 |
| DHLA (μg/mL) | 15 | 3.5 (3.0) | 5.4 (3.2) | −1.8 (−11.5, 7.9) | 0.69 |
| EPA (μg/mL) | 15 | 7.6 (10.7) | −16.9 (11.5) | 24.5 (−11.7, 60.7) | 0.17 |
| AA (μg/mL) | 15 | 14.6 (15.3) | 16.7 (16.4) | −2.0 (−51.8, 47.7) | 0.93 |
| DHA (μg/mL) | 15 | 8.9 (13.7) | −17.4 (14.7) | 26.3 (−19.5, 72.1) | 0.23 |
| RLP-cholesterol (mg/dL) | 15 | 3.5 (1.5) | 0.5 (1.6) | 3.0 (−2.0, 7.9) | 0.21 |
| Lipoprotein(a) (mg/dL) | 15 | −6.2 (1.4) | −0.7 (1.5) | −5.5 (−9.9, −1.1) | 0.018 |
| 8-OHdG (ng/mg creatinine) | 16 | −1.0 (0.5) | −1.3 (0.5) | 0.3 (−1.5, 2.1) | 0.71 |
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; DHLA, dihomo-gamma-linolenic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; DHA, docosahexaenoic acid; RLP, remnant-like particle cholesterol; 8-OHdG, 8-hydroxydeoxyguanosine.